Get the Stockscreener App
11.71
5.40%
+0.60
Zentalis Pharmaceuticals Inc stock is currently priced at $11.71, with a 24-hour trading volume of 494.40K.
It has seen a +5.40% increased in the last 24 hours and a -25.03% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $11.35 pivot point. If it approaches the $11.76 resistance level, significant changes may occur.
Previous Close:
$11.11
Open:
$11.63
24h Volume:
494.40K
Market Cap:
$831.56M
Revenue:
-
Net Income/Loss:
$-292.19M
P/E Ratio:
-2.4396
EPS:
-4.8
Net Cash Flow:
$-208.41M
1W Performance:
+5.88%
1M Performance:
-25.03%
6M Performance:
-34.51%
1Y Performance:
-45.10%
1D Range:
$11.44
$12.11
52W Range:
$9.56
$31.46
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
Name
Zentalis Pharmaceuticals Inc
Sector
Industry
Phone
212 433 3791
Address
530 Seventh Avenue, Suite 2201, New York, NY
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-12-22 | Initiated | Cowen | Outperform |
| Apr-06-22 | Initiated | Wells Fargo | Overweight |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-29-21 | Initiated | Oppenheimer | Outperform |
| May-21-21 | Initiated | UBS | Buy |
| Jan-20-21 | Initiated | Wedbush | Outperform |
| Sep-29-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-27-20 | Initiated | H.C. Wainwright | Buy |
| Apr-28-20 | Initiated | Guggenheim | Buy |
| Apr-28-20 | Initiated | Jefferies | Buy |
| Apr-28-20 | Initiated | Morgan Stanley | Overweight |
| Apr-28-20 | Initiated | SVB Leerink | Outperform |
View All
Zentalis Pharmaceuticals Inc Stock (ZNTL) Latest News
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024
GlobeNewswire Inc.
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Wall Street Analysts Think Zentalis Pharmaceuticals, Inc. (ZNTL) Could Surge 136.44%: Read This Before Placing a Bet
Zacks Investment Research
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Zentalis Pharmaceuticals Inc Stock (ZNTL) Financials Data
Zentalis Pharmaceuticals Inc (ZNTL) Net Income 2024
ZNTL net income (TTM) was -$292.19 million for the quarter ending December 31, 2023, a -23.39% decrease year-over-year.
Zentalis Pharmaceuticals Inc (ZNTL) Cash Flow 2024
ZNTL recorded a free cash flow (TTM) of -$208.41 million for the quarter ending December 31, 2023, a -25.32% decrease year-over-year.
Zentalis Pharmaceuticals Inc (ZNTL) Earnings per Share 2024
ZNTL earnings per share (TTM) was -$4.54 for the quarter ending December 31, 2023, a -0.22% decline year-over-year.
About Zentalis Pharmaceuticals Inc
Zentalis Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers in the United States. Its lead product candidate is the ZN-c5, an oral selective estrogen receptor degrader that is in a Phase I/II clinical trial for the treatment of breast cancer. The company is also developing ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase I/II clinical trial for the treatment of advanced solid tumors; ZN-d5, a selective inhibitor of B-cell lymphoma 2 for the treatment of hematological malignancies; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor that is in Phase I/II clinical trial for the treatment of advanced non-small cell lung cancer. Zentalis Pharmaceuticals, LLC was founded in 2014 and is based in New York, New York.
1.62%
0.15%
Cap:
|
Volume (24h):